Document Detail

A prospective study of pregravid oral contraceptive use in relation to fetal growth.
MedLine Citation:
PMID:  15327615     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Because oral contraceptives are so widely used, any health consequences may have substantial public health implications. Whether pregravid oral contraceptives could affect subsequent pregnancies has not been adequately studied. The study objectives were to examine whether pregravid oral contraceptive use affects fetal growth and pregnancy hormone levels. DESIGN: A prospective study of pregnant women followed through pregnancy. SETTING: A major teaching hospital in Boston, USA. POPULATION: Two hundred and sixty Caucasian pregnant women, with a mean age of 31, and a parity of no more than two. Seventy-nine percent of the women were pregravid oral contraceptive users. METHODS: Exposure and covariate data were collected through structured questionnaires. Blood was drawn for hormonal analysis during the 16th and 27th gestational week. Information on pregravid oral contraceptive use included duration and recency of use, and oral contraceptive formulation. Multivariate regression models were used to examine the effect of pregravid oral contraceptive use on birth outcomes and the studied pregnancy hormones. MAIN OUTCOME MEASURES: Birthweight, placental weight, gestational age, pregnancy hormone levels of oestriol and progesterone at 16th and 27th gestational week. RESULTS: Adjusting for confounders, pregravid oral contraceptive use increased birthweight (mean difference =+207.3 g, 95% CI =+77.6 to +337.1) and placental weight (mean difference =+64.9 g, 95% CI =+13.0 to +116.9) compared with never use. Women with prior oral contraceptive use had higher levels of serum progesterone (P= 0.002) and oestriol (P= 0.12) at the 27th gestational week measurement. The effect on birthweight, placental weight and hormones was stronger among those using oral contraceptives in the previous year and those using a high progestin/high oestrogen potency preparation. CONCLUSIONS: Pregravid oral contraceptive use is positively associated with fetal growth, and this effect may be mediated through oestriol and progesterone.
Lorelei A Mucci; Pagona Lagiou; Chung-Cheng Hsieh; Rulla Tamimi; Susan Hellerstein; Lars Vatten; Hans-Olov Adami; Sven Cnattingius; Dimitrios Trichopoulos
Related Documents :
23337015 - Infant's bilobar thyroid agenesis and mother's i-131 accidental administration.
24741295 - Adherence to intermittent preventive treatment for malaria with sulphadoxine-pyrimetham...
12287765 - Postcoital contraception underrecognized and underutilized.
9749425 - Successful pregnancy in a woman with acute myeloid leukemia treated with high-dose whol...
16258335 - Recent advances in uterine fibroid embolization.
7927695 - Effects of a porphyromonas gingivalis infection on inflammatory mediator response and p...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  111     ISSN:  1470-0328     ISO Abbreviation:  BJOG     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-08-25     Completed Date:  2004-10-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  989-95     Citation Subset:  AIM; IM    
Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Contraceptives, Oral / adverse effects*
Embryonic and Fetal Development / drug effects*
Infant, Low Birth Weight
Infant, Newborn
Maternal Age
Maternal Exposure
Preconception Care
Pregnancy Outcome
Prospective Studies
Grant Support
Reg. No./Substance:
0/Contraceptives, Oral

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Randomised treatment trial of bacterial vaginosis to prevent post-abortion complication.
Next Document:  Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 2...